Nebraska Oncology Society

Nebraska Oncology Society is a non-profit organization that has been in existence since 1992. Our mission is to facilitate and promote interaction among the oncology community to enhance patient care through oncology research, education, and health care legislation.

https://www.nebraskaoncology.org/

 

Annual Regional Midwest ASCO Review 2020
07:33

Nebraska Oncology Society

Targeted Therapy for mNSCLC: What Is the Response Rate With Selpercatinib in RET+ Disease? How Do Treatment Options for MET Exon 14 Compare?

FEATURING Gregory Riely
  • 199 views
  • March 5, 2021
  • 2
15:24

Nebraska Oncology Society

NSCLC Targeted Therapies Update: Should We Consider EGFR Targeted Therapy in Adjuvant Setting?

FEATURING Gregory Riely
  • 159 views
  • March 5, 2021
  • 1
09:41

Nebraska Oncology Society

ASCO 2020 Review of Transoral Robotic Surgery for OPC : Is 2-yr PFS Favorable Without Post-Operative Therapy for Low-risk Disease Patients?

FEATURING Eric Sherman
  • 13 views
  • January 5, 2021
09:24

Nebraska Oncology Society

2020 ASCO LA-HNSCC Trials Review: What Is the Efficacy of Weekly CDDP vs. 3-Weekly CDDP?

FEATURING Eric Sherman
  • 13 views
  • January 5, 2021
11:38

Nebraska Oncology Society

ASCO 2020 Update on DO-IMRT & HNC Metastatic: Does Change in IMRT Lead to Improvement in Swallowing Function? What Are the KEYNOTE-048 Final Results Not Telling Us?

FEATURING Eric Sherman
  • 20 views
  • January 5, 2021
04:56

Nebraska Oncology Society

2020 ASCO Update on Metastatic/Recurrent HNSCC: What Is the Efficacy and Tolerance of Carboplatin-Cetuximab? Is Single-Agent Chemotherapy Sufficient?

FEATURING Eric Sherman
  • 15 views
  • January 5, 2021
08:09

Nebraska Oncology Society

2020 ASCO Update on RET-Altered Thyroid Cancer: What Is the Efficacy of New RET Inhibitors? Should We Use Them 1L or 2L?

FEATURING Eric Sherman
  • 25 views
  • January 5, 2021
06:13

Nebraska Oncology Society

Nebraska Oncology Society 2020 Update on Advanced UC: Is Atezo Beneficial for DFS in High-Risk Muscle-Invasive Disease? Should We Add Avelumab After 1L Platinum-Based Chemo?

FEATURING Nicholas Vogelzang
  • 48 views
  • December 7, 2020
17:42

Nebraska Oncology Society

Nebraska Oncology Society 2020 Update on PC: Does 18F-DCFPyL-PET/CT Propose a Change in Biochemically Relapsed Disease? Can Enzalutamide Delay Mets in Men With CRPC? Does Darolutamide Prolong OS?

FEATURING Nicholas Vogelzang
  • 118 views
  • December 7, 2020
13:26

Nebraska Oncology Society

Nebraska Oncology Society 2020 Update on Advanced RCC: Is 1L Pembro+Axitinib More Beneficial for OS/PFS vs. Sunitiniby? What Is the ORR With Nivo+Ipi vs. Nivo Mono in Treatment-Naïve Patients?

FEATURING Nicholas Vogelzang
  • 170 views
  • December 7, 2020
11:59

Nebraska Oncology Society

2020 ASCO mCRC Updates Recap: Did We Experience Pseudoprogression With Pembro? Is Toxicity Equally Important as Efficacy? Should We Still Use SCRT as a SoC?

FEATURING George Kim
  • 48 views
  • November 30, 2020
05:11

Nebraska Oncology Society

2020 ASCO Updates on GI Cancers: Is Chemo w/ mFOLFIRINOX More Effective vs. Gemcitabine/nab-Paclitaxel in Resectable PDAC? Should We Use 1L Donafenib vs. Sorafenib in Advanced HCC?

FEATURING George Kim
  • 13 views
  • November 30, 2020
10:06

Nebraska Oncology Society

2020 ASCO Highlights on Advanced CRC: Does mFOLFIRINOX Show DFS Benefit vs. Chemoradiation Among LARC Patients? Is Encorafenib+Cetuximab+/-Binimetinib Effective for BRAF V600E Mutations? What Is the ORR With T-DXd in HER2+ Metastatic Disease?

FEATURING George Kim
  • 15 views
  • November 30, 2020
04:13

Nebraska Oncology Society

2020 ASCO Updates on mCRC: Is Adjuvant mFOLFOX Superior to Hepatectomy Alone for Liver Metastases?

FEATURING George Kim
  • 25 views
  • November 30, 2020
07:52

Nebraska Oncology Society

2020 ASCO Highlights on Stage 3 Colon Cancer: What Are the DFS/OS Differences Between 3 vs. 6 Months of Adjuvant FOLFOX/CAPOX? Is the Addition of Celecoxib Beneficial?

FEATURING George Kim
  • 21 views
  • November 30, 2020
10:48

Nebraska Oncology Society

KEYNOTE-177 2020 ASCO Update on MSI-H/dMMR mCRC: Does Pembro Improve PFS vs. Chemo? Is It Practice Changing?

FEATURING George Kim
  • 28 views
  • November 30, 2020
07:39

Nebraska Oncology Society

ES-SCLC 2020 Update: Which IO Options Showed Activity in Phase III Trials? How Effective Is Lurbinectedin in Stage IV Disease Progressed After 1L Therapy?

FEATURING Gregory Riely
  • 93 views
  • October 13, 2020
16:08

Nebraska Oncology Society

Stage IV NSCLC 2020 Update: Is There a Benefit to Short-Course Chemotherapy and IO Combination in Disease Without an Oncogenic Driver?

FEATURING Gregory Riely
  • 122 views
  • October 13, 2020
30:39

Nebraska Oncology Society

2020 ASCO Updates on IO in Advanced Melanoma: What Are the Outcomes With Different Ipi+Nivo Combinations? How Do Targeted Therapy Agents Compare to IO? Does Pembro Lead to Lower irAEs?

FEATURING Shailender Bhatia
  • 65 views
  • October 12, 2020
10:23

Nebraska Oncology Society

2020 ASCO Highlights on Neoadjuvant IO in Stage 3 Melanoma: Does Ipi Lead to Lower Toxicity? Are There Benefits Over Standard Therapy?

FEATURING Shailender Bhatia
  • 43 views
  • October 12, 2020
21:02

Nebraska Oncology Society

2020 ASCO Updates on Frontline Multiple Myeloma: KRd vs. VRd - What Does the PFS/OS Analysis Suggest?

FEATURING Adam D. Cohen
  • 302 views
  • October 12, 2020
25:01

Nebraska Oncology Society

2020 ASCO Updates on R/R Myeloma: Does FDA-Approved Selinexor Offer Survival Benefit? What Are the Response Rates With Teclistamab?

FEATURING Adam D. Cohen
  • 335 views
  • October 12, 2020
  • 1